SUPERNUS PHARMACEUTICALS INC 4
4 · SUPERNUS PHARMACEUTICALS INC · Filed Mar 31, 2015
Insider Transaction Report
Form 4
Bryan Jones W.
VP of Business Development
Transactions
- Exercise/Conversion
Common Stock
2015-03-30$2.56/sh+6,712$17,183→ 74,692 total - Sale
Common Stock
2015-03-30$12.02/sh−6,712$80,647→ 67,980 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2015-03-30−6,712→ 30,763 totalExercise: $2.56Exp: 2020-11-02→ Common Stock (6,712 underlying)
Footnotes (3)
- [F1]Transaction made pursuant to a Rule 10b5-1 trading plan adopted on April 21, 2014.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.1000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The option vested in four equal annual installments beginning on November 2, 2011.